Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Amended ATM enables discretionary common-stock sales through Leerink and Cantor under Form S-3 registration.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Amended ATM enables discretionary common-stock sales through Leerink and Cantor under Form S-3 registration
- Prior agreement authorized up to $100.0 million of common-stock sales
- 3.0% commission on gross proceeds, increasing the cost of any equity financing
- No obligation to sell, preserving funding flexibility while leaving potential shareholder dilution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.